OncBioMune LLC

Therapeutic Vaccines – Breast and Prostate

Cancer

Novel Cancer Drugs

This opportunity is brought to you by Aagami, Inc. , a life sciences consulting firm based in the suburbs of Chicago, brings exciting opportunities from global companies having innovative technologies and products to India and Emerging Markets.

Bringing innovative cancer therapy to the world and high profitability to its partners

1

• OncBioMune has a pipeline of both targeted therapies and therapeutic vaccines

• Both have been shown to be more effective and less toxic than conventional chemotherapies.

• OncBioMune is currently looking for corporate partners to further develop their technologies. They seek to develop cancer vaccines and targeted drugs through Phase II Clinical Trials.

• Return on investment estimated to be minimum 10X (e.g. Investing $5Mn would yield minimum $50Mn)

• Opportunity in innovative cancer treatments, cancer vaccines and drug technologies , that you could license and/or co-develop

• OncBioMune LLC, is a 30 year old Baton Rouge, Louisiana based biotechnology company specializing in innovative cancer treatments, has proprietary rights to a breast cancer vaccine, prostate cancer vaccine and the targeted chemotherapy Paclitaxel- Gallium-Transferrin

Opportunity in Innovative Cancer Therapy, with ROI 10x of Investment possibility

2

The Pipeline:

Therapeutic Cancer Vaccines

Safety and Efficacy demonstrated by extensive internal clinical trials. Several Hundred people have received thousands of vaccines with very little toxicity.

Prostate Cancer Vaccine “Prostatac”

– In-House clinical trails have shown a 2/3 response rate

– PSA stimulates patients immune system to fight cancer

– Presently starting Clinical Trials

• Department of Defense ($ 5,200,000 over 5 years)

• Elona BioTechnologies, Inc - Protein Manufacturer

• CRO Theradex® Oncology

• Fully Funded Phase 1a/1b clinical trial hosted by the Moore’s Cancer Center at University of California San Diego Medical School

Breast Cancer Vaccine • Initially developed in 1993; in clinic use since 1994

3

Lead Vaccine Candidate PSA Vaccine “Prostatac”

• Off the Shelf Vaccine Technologies

• Components

– PSA Antigen

– IL-2 Stimulates the effector cells

– GM-CSF Promotes Antigen presentation to Dendritic Cells

+ PSA IL-2 GMCSF

+

Majority of Patients had declining PSA after the Vaccine

4

Sample Vaccination Responses

DIAGNOSIS DATE OF 1ST VACCINE

PSA BEFORE VACCINE

PSA AFTER 6 VACCINES

PSA AFTER 12 VACCINES

LAST PSA

(MONTHS)

Prostate Ca 06/13/97 4.10 2.40 2.50 3.50 (80)

Prostate Ca 04/22/99 1.04 0.60 0.66 0.90 (92)

Prostate Ca 07/27/99 6.80 6.40 only 6 vaccines ----

Prostate Ca 11/30/99 4.90 2.80 2.40 2.97 (42)

Prostate Ca 02/10/00 6.20 5.80 1.90 2.20 (65)

Prostate Ca 02/28/00 4.20 3.50 4.40 3.90 (18)

Prostate Ca 03/06/00 14.60 5.50 6.50 7.70 (49)

Prostate Ca 06/27/00 7.60 13.70 only 4 vaccines

Prostate Ca 08/08/00 4.00 4.93 seeds ----

Prostate Ca 03/22/01 8.95 10.60 17.19 ----

Prostate Ca 05/21/01 7.20 5.41 7.30 6.00 (28)

Prostate Ca 06/04/01 4.55 7.02 4.17 10.80 (21)

Benign Hyper 07/12/99 8.90 8.70 9.60 15.30 (13)

Prostatitis 09/23/99 6.22 5.70 6.30 ----

Results from internal clinical trial done in accordance with physician/ compounding pharmacy laws.

5

Highlights & Clinical Trial

• IND # 14778 • Fully funded phase 1a/1b clinical

trial to commence the first quarter of 2013 at the UCSD Moore's Cancer Center.

• Batched cGMP PSA produced, fill finished and in storage at Bio-storage technologies.

• Animal Toxicology performed by MPI showed no toxicity.

• Phase 1a – Vaccinate 20 patients to

confirm minimal toxicity of the PSA vaccine

• Phase 1b – Enroll 28 additional patients

• Partnering with UCSD Medical Center

NCVP Phase 1a and 1b Clinical Trial Highlights - PSA Vaccine

Highlights & Clinical Trial

6

Kaplan-Meier Curve Shows Improved Survival of Breast

Cancer patients with depressed immunity

Vaccination study using OBM vaccine technology

Vaccinated depressed immunity

89% (33/37)

59% (33/56)

95% (20/21)

7

Treated Patient Population

Cancer Type Number of Patients

Breast 210

Prostate 26

Colon 4

Ovarian 4

Lung 4

Melanoma 2

Sarcoma 2

Stomach/Esophageal 1

Facial Skin 1

Tongue 1

TOTAL 255

*The patient population came for the Elliott-Elliott-Head Breast Cancer Research and Treatment Center.

8

Drugs currently on the Market

*Estimated Revenues for 2016 in the US

Provenge $940 million

Zytiga $1,500 million

Opportunity assessment of “Prostatac”

Prostate Cancer in the US 2.2 Million Men in the US with Prostate Cancer •242,000 new cases in 2012 (NCI) •28,000 Deaths.. •845,000 of those men are undergoing androgen deprivation therapy (Bernstein Research)

*Forecasted growth at 5% per year *Forecasts from Evaluate Pharma

9

5-Year Timeline for Prostatac

Phase I clinical trial for prostate cancer vaccine underway

Phase I clinical trial for prostate cancer vaccine completed

Phase II clinical trial for prostate cancer

License agreements pursued for late stage development of prostate cancer vaccine

Prostate cancer vaccine licensed

Prostatac

10

Novel Cancer Drugs

Pipeline:

Paclitaxel Gallium Transferrin

+ +

“PGT”

Targeted Therapy PGT Innovative Chemotherapy

Drug

•Transferrin targets paclitaxel to cancer cells

and delivers it into the cytoplasm beyond

drug efflux protein pumps

•Avoids use of Cremophor EL in paclitaxel

preparation

•Has increased efficacy due to decreased

toxicity, and increased specificity compared

to other chemotherapeutic drugs

•Drug can be used to treat various forms of

cancer including Breast, Prostate, Ovarian

and Multiple Myeloma. Decreased Toxicity, Increased specificity

11

Studies

MCF-7 Study PGT Animal Study

12

PGT Opportunity Assessment

If PGT captures X% of

the taxane market…

Peak sales in 2023 are

estimated to be…

1% $194M

2% $387M

3% $581M

4% $775M

5% $968M

6% $1.2B

7% $1.4B

8% $1.6B

9% $1.7B

10% $1.9B

7.2%

11.9%

6.4%

2.8%

6.4%

2.2%

0%

2%

4%

6%

8%

10%

12%

14%

2008 2013 2018

DecisionResources

Sell-Side Analyst(MCF)

Note: Sell-side analyst estimate for percentage of taxane market

captured by Abraxane calculated by dividing estimated Abraxane sales

by the price of therapy per patient estimated by Decision Resources to

get number of patients on Abraxane. That figure was then divided by

the Decision Resources estimate for number of patients on taxanes

across breast, NSCLC, prostate, gastric, melanoma, and ovarian

cancers.

Estimated Percent of Overall

Taxane Market Captured by

Abraxane

Assumptions:

• The overall taxane market continues to grow at the same annual rate as

it is currently estimated by Decision Resources to grow between 2008

and 2018 in the US

• PGT generates revenue per patient per year equivalent to what Abraxane

generates currently per patient per year (no growth rate in price)

If PGT can capture just a small percentage of the taxane market in the US,

that Abraxane is expected to capture, it could be a blockbuster product.

2.8%

6.4% 7.2%

2.2%

6.4%

11.9%

0%

2%

4%

6%

8%

10%

12%

14%

2008 2013 2018

Decision Resources

Sell-Side Analyst (MCF)

13

5-Year Timeline for Targeted Therapy PGT

Develop Manufacturing process for PGT

IND application filed for PGT treatment of Stage IV ovarian cancer

Phase I trial for PGT for Stage IV Ovarian Cancer I initiated

Phase I for PGT in breast cancer

Licensing agreements pursued for PGT use in Stage IV Ovarian Cancer

14

The Opportunity to yield ROI of 10X

• You can In-license for India/Asia OR

• Co-develop vaccines and drugs thru Phase II Clinical Trials

• Out-license together to a Major Pharma on completion of Phase III

• This offering is sure to yield 10X of your investment made

OncBioMune is looking for

corporate partners to further develop their technologies

and products...

OR

In-license for emerging markets

15

Join us in our conversations at,

Contact us for more information Let’s get in touch…

Global Life Science Business in India

Our Linkedin group initiative

Aagami Home www.aagami.net

Research Reports, Presentations, Newsletter, and more…

USA (Head Office) 2020 Calamos Ct. Suite 209 ,

Naperville, IL 60653

Phone: +1-630-799-1572

Contact Dinesh Jain

Email: dinesh@aagami.net

Cell: +1 -630-853-3520

INDIA Crystal Plaza, Level 2,

276 C B Road, Ramdaspeth

Nagpur – 440010

Contact Godwyn Francis

Email: godwyn@aagami.net,

Cell: +91-787-501-6957

Realizing Possibilities

Supporting Global Lifesciences companies exploring India and Emerging Markets

16